Director – Vaccine Portfolio Strategy & External Partnerships
About the job
- A bachelor's degree in a science, business, healthcare, or related discipline is required.
- A minimum of 10 years of relevant experience in pharmaceuticals, biotechnology, vaccines, healthcare strategy, portfolio planning, global commercial strategy, business development, market access, portfolio governance, or management consulting is required, with a scientific background or demonstrated ability to integrate scientific and clinical evidence into commercial and portfolio decisions.
- Experience leading commercial assessments, opportunity evaluations, strategic diligence, and business case development for pipeline, lifecycle, or external partnership opportunities is required.
- Strong knowledge of vaccine commercialization, including lifecycle strategy, launch planning, market access, pricing, payer dynamics, global commercial considerations, and regional market dynamics across U.S. and international markets, is required.
- Advanced analytical and financial capabilities, including market sizing, scenario planning, valuation inputs, sensitivity analysis, investment trade-off assessment, and risk assessment, are required.
- Demonstrated matrix leadership, including the ability to influence senior stakeholders, lead cross-functional teams, and communicate clear recommendations under ambiguity, is required.
- Experience working with regional and global teams and synthesizing differences in U.S. and international market dynamics, access environments, customer needs, policy considerations, and commercial execution requirements is required.
- Strategic thinking and commercial assessment expertise, including the ability to anticipate market shifts and create high-value deliverables from white space, is required.
- Strong pharmaceutical and vaccine commercialization knowledge, including lifecycle strategy, launch excellence, market access, pricing, business development, and strategic marketing frameworks, is required.
- Business case development, forecasting, market sizing, valuation, scenario planning, and investment prioritization capabilities are required.
- Knowledge of AI and its application in R&D capabilities to assess opportunities through evidence synthesis, target/product profile evaluation, development feasibility, assumption testing, scenario modeling, and risk identification is required.
- External-facing leadership to guide commercial discussions, support negotiation strategy, and collaborate with Legal on confidential disclosure agreements, material transfer agreements, service agreements, and related contracting processes is required.
- Data-driven decision-making using clinical evidence, market research, competitive intelligence, policy, and regional insights is required.
- Strong cross-functional leadership, the ability to lead without authority, clear executive communication and stakeholder influence, executional excellence, prioritization, judgment, and learning agility are required.
- Own execution of vaccine portfolio planning across inline, lifecycle, pipeline, and external opportunities, synthesizing diverse insights, pressure-testing assumptions, shaping recommendations, and driving clarity through a decision-gate approach aligned with enterprise strategy and business objectives.
- Translate internal and external pipeline priorities into actionable portfolio plans, investment recommendations, and execution roadmaps.
- Develop structured business cases, opportunity screens, prioritization frameworks, valuation inputs, scenario models, risk assessments, and strategic rationale to support portfolio and investment decisions.
- Lead commercial and portfolio assessments for internal and external opportunities by integrating market, epidemiology, clinical, access, pricing, competitive, financial, and R&D inputs.
- Apply AI knowledge to assess opportunities, including evidence synthesis, target/product profile evaluation, development feasibility, scenario modeling, assumption testing, and risk identification.
- Partner with Research, Clinical Development, Medical Affairs, Global Market Access & Pricing, Business Planning, Manufacturing & Supply, Legal, and regional teams to evaluate strategic fit, commercial attractiveness, risk-adjusted value, and implementation feasibility, and ensure these inputs are reflected in portfolio assessments and business cases.
- Lead external-facing commercial discussions with potential partners, vendors, and customer-facing stakeholders to frame opportunity assessments, clarify assumptions, support negotiation strategy, and advance business case alignment.
- Collaborate with Legal and External Partnerships/Business Development to support contract-related inputs for confidential disclosure agreements, material transfer agreements, service agreements, and related partner/vendor arrangements.
- Lead strategic diligence for new vaccine targets, platform opportunities, lifecycle investments, and portfolio expansion options through a commercial lens.
- Support stage-gate and portfolio governance by preparing decision materials, tracking asset assessment status, escalating risks or evidence gaps, and capturing lessons learned.
- Influence prioritization, funding, resource allocation, and investment decisions across short- to long-term time horizons through evidence-based recommendations.
- Influence and communicate across organizational levels and cross-functional audiences, adapting style and approach to drive alignment, clarity, and timely decision-making.
- Translate complex insights into clear recommendations for senior leaders and stakeholders.
- Build internal and external partnerships to advance portfolio strategy, business case quality, negotiation readiness, executional excellence, and value optimization.
- Lead or support time-bound strategic assessments and business case work, including commercial opportunity assessments for pipeline assets, platform technologies, market-entry options, and external partnership candidates.
- Prepare decision-ready business cases and governance materials for investment, licensing, co-development, co-commercialization, and portfolio prioritization decisions.
- Support external opportunity discussions and negotiation, including commercial input into confidential disclosure agreements, material transfer agreements, service agreements, and related contracting processes in partnership with Legal and External Partnerships/Business Development.
- Apply AI knowledge and R&D capabilities to strengthen opportunity assessment, including clinical-stage asset evaluation, evidence synthesis, development feasibility, scenario planning, assumption testing, risk visibility, and governance readiness.
- Integrate clinical, commercial, access, financial, operational, legal/contracting, and risk assumptions into recommendations supporting investment decisions, partner discussions, negotiation readiness, and future value creation.
- Represent the commercial perspective in external discussions with potential partners, vendors, and customer-facing stakeholders, and collaborate with Legal and External Partnerships/Business Development on contracting inputs.
- Synthesize incomplete information, pressure-test assumptions, and use a decision-gate approach to align stakeholders on trade-offs, options, and practical next steps.
- An advanced scientific/medical degree, a Master of Science, or a Master of Business Administration is preferred.
About the company
CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.
Company Size
10,001+
Company Stage
IPO
Headquarters
Parkville, Australia
Founded
1916
Get referred to CSL
See people who can refer or advise you
Simplify's Take
What believers are saying
- CSL reported US$176 million FY26 cost savings, ahead of its transformation target.
- US military flu-vaccine exceptions restored some demand after April 2026 mandate cuts.
- VarmX’s 2029 coagulation program gives CSL a new high-value pipeline beyond plasma.
What critics are saying
- FY26 statutory loss hit US$2.6 billion after US$7.1 billion impairments and restructuring.
- CSL plans US$400 million FY27 savings, implying more closures, layoffs, and execution friction.
- The U.S. plasma turnaround depends on Horizon 2; failure risks long-term margin collapse.
What makes CSL unique
- CSL’s FY26 revenue reached US$15.8 billion across plasma, vaccines, and Vifor.
- Seqirus’ AUJEMFLU won UK and European approvals, backed by Lancet Phase 3 data.
- HEMGENIX remains Europe’s first approved hemophilia B gene therapy, strengthening CSL Behring.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Time Off
Paid Vacation
Paid Sick Leave
Paid Holidays
Growth & Insights and Company News
6 month growth
0%1 year growth
0%2 year growth
1%Haemonetics shares jumped 12% after the company announced CSL now expects to move all of its current US plasma collection centres to Haemonetics' NexSys devices by the end of 2027. The deal, first disclosed in August, was initially limited to only a portion of CSL's US centres with no timeline. The expanded agreement is significant because losing CSL previously flattened Haemonetics' growth. In fiscal 2026, the company's organic revenue growth was just 1.1%, compared to 9.5% excluding lost CSL sales. Following the surge, Haemonetics trades at approximately 21 times forward earnings, above its five-year average of 19.1 times. The deal is non-exclusive with no minimum purchase requirements, meaning CSL can still modify scope and timing. Management plans to provide further details during its November earnings call.
CSL has raised US$1.5 billion through corporate bonds issued in the United States to refinance existing debt. The Australian biotechnology company turned to offshore debt markets for the transaction. The bond issuance allows CSL to manage its capital structure by replacing current borrowings with new financing secured from US investors.
Melbourne, Australia – 16 September 2025 CSL today announced it has entered into a strategic collaboration with privately held Dutch biotech company VarmX BV to support the company’s...
CSL Seqirus has published Phase 3 study results in The Lancet Infectious Diseases for its MF59-adjuvanted cell-based higher-dose quadrivalent influenza vaccine for older adults. The vaccine, marketed as AUJEMFLU, combines three proven approaches: MF59 adjuvant, cell-based manufacturing, and higher-dose formulation. The randomised study enrolled 7,699 adults aged 50 and older across eight countries. Results demonstrated superiority versus an adjuvanted egg-based comparator across all four influenza strains and age groups. The vaccine showed non-inferiority versus a recombinant vaccine for three of four strains in the 50-plus age group and all four strains in those aged 65-plus. The trivalent formulation received approval from the UK's MHRA and the European Commission earlier this year for adults aged 50 and above. Regulatory submissions have been made in multiple markets.
Australian biopharmaceutical company CSL reported a 2% decline in annual profit on Tuesday, as its core plasma division experienced falling revenue. The company posted an underlying net profit after tax of $3.14 billion on a constant currency basis for the year ended 30 June, down from $3.22 billion the previous year. CSL is among the world's leading flu vaccine manufacturers. The results reflect challenges in the plasma business, which forms a significant part of the company's operations.